LAVA Therapeutics (LVTX) Stock Price, News & Analysis

Company Overview

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Key Stats

• Today's Range: $1.52 to $1.56
• 50-Day Range: $1.29 to $1.53
• 52-Week Range: $0.85 to $2.09
• Volume: 105,979 shs
• Average Volume: 207,540 shs
• Market Capitalization: $40.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.69
• Consensus Rating: Hold

LAVA Therapeutics Stock Analysis - MarketRank™

LAVA Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 739th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

LAVA Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

LAVA Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LAVA Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LAVA Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LAVA Therapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.29% of the float of LAVA Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LAVA Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LAVA Therapeutics has recently decreased by 28.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LAVA Therapeutics does not currently pay a dividend.

Dividend Growth

LAVA Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.29% of the float of LAVA Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LAVA Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LAVA Therapeutics has recently decreased by 28.05%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.00

News Sentiment

LAVA Therapeutics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for LAVA Therapeutics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for LVTX on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added LAVA Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.50% of the stock of LAVA Therapeutics is held by insiders.

LVTX Stock Analysis - Frequently Asked Questions

How have LVTX shares performed this year?

LAVA Therapeutics' stock was trading at $0.9510 on January 1st, 2025. Since then, LVTX stock has increased by 61.9% and is now trading at $1.54.

How were LAVA Therapeutics' earnings last quarter?

LAVA Therapeutics N.V. (NASDAQ:LVTX) announced its quarterly earnings results on Tuesday, August, 19th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.04.

When did LAVA Therapeutics IPO?

LAVA Therapeutics (LVTX) raised $100 million in an IPO on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Kempen & Co. was co-manager.

Who are LAVA Therapeutics' major shareholders?

LAVA Therapeutics' top institutional investors include BML Capital Management LLC (7.49%).

How do I buy shares of LAVA Therapeutics?

Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LAVA Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LAVA Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), New Oriental Education & Technology Group (EDU), ServiceNow (NOW) and AppLovin (APP).

Company Calendar

• Today: 8/14/2025
• Last Earnings: 8/19/2025
• Next Earnings (Estimated): 8/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LVTX
• CIK: 1840748
• Web: www.lavatherapeutics.com
• Phone: 31-85-016-3100
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for LAVA Therapeutics: $2.69
• High Price Target: $6.00
• Low Price Target: $1.24
• Potential Upside/Downside: +74.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.11 million
• Net Margins: N/A
• Pretax Margin: -545.07%
• Return on Equity: -86.38%
• Return on Assets: -34.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.73
• Quick Ratio: 6.73

Sales & Book Value

• Annual Sales: $4.99 million
• Price / Sales: 8.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.06 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 26,305,000
• Free Float: 23,806,000
• Market Cap: $40.51 million
• Optionable: Optionable
• Beta: 0.50